Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.35 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.34 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24153922 | 0.88 | RIPK1 (0.47) | BRD4ALDH1A1GLARIPK1C5AR1 | |
| SCHEMBL2263864 | 0.85 | KDM4C (0.40) | RIPK1MCHR1 | |
| SCHEMBL20083011 | 0.84 | MCHR1 (0.48) | BRD4ALDH1A1GLARIPK1MCHR1 | |
| SCHEMBL12366340 | 0.82 | BRD4 (0.42) | BRD4ALDH1A1GLARIPK1PKM | |
| SCHEMBL12366338 | 0.81 | ALDH1A1 (0.35) | BRD4ALDH1A1GLARIPK1PDE10A | |
| SCHEMBL1013919 | 0.81 | PDE4B (0.37) | BRD4ALDH1A1RIPK1PDE4BHCRTR2 | |
| SCHEMBL5524936 | 0.79 | HPGD (0.46) | RIPK1 | |
| SCHEMBL12366343 | 0.79 | RIPK1 (0.41) | BRD4ALDH1A1GLARIPK1C5AR1 | |
| SCHEMBL12366333 | 0.76 | ALDH1A1 (0.38) | BRD4ALDH1A1GLARIPK1PKM | |
| SCHEMBL12366346 | 0.76 | RIPK1 (0.41) | BRD4ALDH1A1GLARIPK1C5AR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003006-B2 | Difluorobenzene derivative and nematic liquid crystal composition using the same | DAINIPPON INK AND CHEMICALS, INC. (JP) | 2011-08-23 | — | — | US | disclosed |
| US-20090200514-A1 | DIFLUOROBENZENE DERIVATIVE AND NEMATIC LIQUID CRYSTAL COMPOSITION USING THE SAME | DAINIPPON INK AND CHEMICALS, INC. (JP) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090200514-A1 | DIFLUOROBENZENE DERIVATIVE AND NEMATIC LIQUID CRYSTAL COMPOSITION USING THE SAME | TRPV2, HCN2, DVL1 | BRD4 1771/4885ALDH1A1 4012/4885GLA 1536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.